Patent ID: 11965026
Assignee: KYMAB LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An immunocytokine comprising
an IL-2 cytokine linked to a C-terminal end of a light chain of an immunoglobulin,
wherein the light chain of the immunoglobulin comprises in N- to C-terminal direction:
a) a VL domain comprising CDRL1, CDRL2 and CDRL3;
b) a light chain constant region, (CL); and
wherein the VL domain comprises
i) the CDRL1 sequence of SEQ ID NO: 37 or 40; and
ii) the CDRL2 sequence of SEQ ID NO: 38 or 41 or the CDRL2 sequence of light chain sequence SEQ ID NO: 50; and
iii) the CDRL3 sequence of SEQ ID NO: 39 or 42; and

wherein the immunocytokine further comprises a heavy chain that comprises in N- to C-terminal direction:
a) a VH domain comprising CDRH1, CDRH2 and CDRH3; and
b) a heavy chain constant region (CH); and
wherein the VH domain comprises
i) the CDRH1 sequence of SEQ ID NO: 27 or 30; and
ii) the CDRH2 sequence of SEQ ID NO: 28 or 31; and
iii) the CDRH3 sequence of SEQ ID NO: 29 or 32 and, the immunocytokine optionally further comprises a linker, (L) that links the IL-2 cytokine to the C-terminal end of the light chain; wherein the VH domain and VL domain are comprised by an antigen-binding site that specifically binds to hPD-L1 as defined by SEQ ID NO: 1 and that inhibits binding of PD-L1 to PD-1.